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Abstract  
 
Background and Purpose: Stroke following percutaneous coronary intervention (PCI) is a 
serious complication, but its determinants and outcomes following PCI in different clinical 
settings are poorly documented.  
Methods: The British Cardiovascular Intervention Society (BCIS) database was used to 
study 560,439 patients who underwent PCI in England and Wales between 2006 and 2013. 
We examined procedural type specific determinants of ischemic and hemorrhagic stroke and 
the likelihood of subsequent 30-day mortality and in-hospital major adverse cardiovascular 
events (MACE; a composite of in-hospital mortality, myocardial infarction or re-infarction 
and repeat revascularization).  
Results: A total of 705 stroke cases were recorded (80% ischemic). Stroke following an 
elective PCI or PCI for ACS indications was associated with a higher risk of adverse 
outcomes compared to those without stroke; 30-day mortality and MACE outcomes in fully 
adjusted model were ORs 37.90(21.43-67.05) and 21.05 (13.25-33.44) for elective and 
5.00(3.96-6.31) and 6.25(5.03-7.77) for ACS, respectively.  Comparison of odds of these 
outcomes between these two settings showed no differences; corresponding ORs were 
1.24(0.64-2.43) and 0.63(0.35-1.15), respectively.  
Conclusions: Hemorrhagic and ischemic stroke complications are uncommon but serious 
complications that can occur following PCI and are independently associated with worse 
mortality and MACE outcomes in both the elective and ACS setting irrespective of stroke 
type. Our study provides a better understanding of the risk factors and prognosis of stroke 
following PCI by procedure type allowing physicians to provide more informed advice 
around stroke risk following PCI and counsel patients and their families around outcomes if 
such neurological complications occur.  
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 Introduction 
Stroke is a serious complication following percutaneous coronary intervention (PCI). 
We and others have previously shown that it is associated with high in-hospital mortality [1-
4] and causes life changing disabilities in those who survive [5-7]. Previous studies were 
conducted in both single centre [8-9] and multicentre settings [1,2] and reported the incidence, 
major determinants and outcomes of stroke following PCI.  
PCI is performed either electively or in the setting of an acute coronary syndrome 
(ACS) as a non-elective (urgent/emergency) procedure. The clinical and procedural 
characteristics in these two settings are different [10,11], and it is conceivable that risk factors 
for stroke during these two clinical scenarios are likely to differ with different impacts on 30-
day mortality and MACE (in-hospital major adverse cardiovascular events) associated with 
stroke. Indeed, Werner and colleagues have recently reported differences in determinants of 
stroke in different clinical settings but were unable to examine this issue specifically for 
ischemic and hemorrhagic stroke separately [2]. Better understanding of such determinants is 
important as these stroke subtypes have different pathophysiologies, different risk profiles 
and different survival trajectories [12].  These cannot be tested in randomised trial setting and 
such real world events needed to be observed and reported through registry data.   
In this study, we examined the determinants and outcomes of ischemic and 
hemorrhagic stroke associated with PCI for ACS compared with those who underwent 
elective PCI using the British Cardiovascular Intervention Society registry in England and 
Wales including over half a million participants. The key objectives of the current study are 
therefore (1) to examine (a) the determinants and (b) factors associated with mortality and 
MACE following ischemic and hemorrhagic stroke following PCI in the ACS and elective 
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settings separately; and (2) to compare the outcomes of the strokes following PCI between 
two clinical settings.  
 
Methods 
Data for the current study were taken from the British Cardiovascular Intervention 
Society (BCIS) dataset, which records all PCI procedures conducted in the UK.  The data 
contains over 100 variables on clinical, procedural and outcome information with 
approximately ~80,000 new records added each year. In-hospital outcomes are recorded on 
the database and mortality outcomes tracked through the Medical Research Information 
Service (MRIS) using the patients’ National Health Service number.  
The main exposure variable for the analysis was whether the PCI procedure was 
carried out as an elective or for ACS. The main outcomes were in-hospital MACE and 30-day 
mortality associated with stroke following PCI. Major adverse cardiac events (MACE) were 
defined as a composite of in hospital mortality, myocardial infarction or repeat intervention. 
We defined stroke-related mortality as mortality among patients who developed stroke 
complications after PCI. Other variables included as potential confounders are described in 
Supplementary Data 1. 
Statistical analysis  
Statistical analyses were performed using Stata Version 13.0 (College Station, Texas, 
USA).  Descriptive statistics were presented by indication (elective cases or PCI for acute 
coronary syndrome) and stroke subtype (ischemic and hemorrhagic stroke). Multiple 
imputations by chained equations were used to account for missing variables with 10 imputed 
datasets.  All the non-outcome variables were then put into multiple logistic regression 
models to identify independent predictors of ischemic and hemorrhagic stroke subtypes 
separately according to indication of PCI.  To calculate the impact of ischemic stroke and 
4 
 
hemorrhagic stroke on in-hospital MACE and 30-day mortality, we used multiple logistic 
regressions controlled for all available covariates and executed separately for elective and 
ACS.   
We then assessed the odds of these adverse outcomes in PCI for ACS using elective 
PCI procedure as the reference category in those who had stroke as a complication of PCI. 
We used a step-wise modeling approach to better understand the associations and the 
following models were constructed.  The models are described in Supplementary Data 1. 
To account for baseline differences across stroke groups, multiple imputations with 
propensity score matching (mi estimate: teffects psmatch on Stata) was used to estimate the 
average treatment effect (ATE).  The method was used to analyze two separate logistic 
treatment models (ischemic stroke vs. no stroke and any stroke vs. no stroke), calculating 
propensity scores for group membership. Additional descriptions of the analysis methods are 
described in Supplementary Data 1. 
Results 
 A total of 588,636 patients underwent either elective PCI or PCI for ACS in England 
and Wales between 2006 and 2013. After exclusion of 28,197 patients with missing 
information on stroke subtype, indication for PCI, age, and sex, a total of 560,439 patients 
were included in the analysis. More than 50% of variables (14/25) had missing data less than 
5%, and 80% (20/25) had <10% missing values (Supplementary Table 1). A total of 705 
patients (0.13%) experienced an in-patient stroke complication following PCI of whom 566 
patients (0.10%) sustained an ischemic stroke and 139 patients (0.02%) sustained a 
hemorrhagic stroke.  
Table 1 shows the differences in the sample characteristics between patients who had 
ischemic and hemorrhagic stroke and those who did not stratified by PCI setting.  Older age, 
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female sex and requirement to use glycoprotein IIb/IIIa inhibitors were significantly 
associated with ischemic stroke as a complication after elective PCI. Patients with a 
confirmed stroke post elective PCI had a significantly higher incidence of in-hospital MACE 
and 30-day mortality. In the setting of PCI for ACS, the demographic profile associated with 
an ischemic stroke was similar, but with a wider age difference; mean age difference was 5.4 
years compared to 2.2 years observed in the elective setting. Female sex, history of previous 
stroke, cardiogenic shock and requirement for circulatory support, glycoprotein IIb/IIIa 
inhibitor use and left main stem disease were significantly associated with the complication 
of hemorrhagic stroke post elective PCI. Those with hemorrhagic stroke post elective PCI 
had a considerably higher rate of in-hospital MACE and 30-day mortality than those without 
stroke.  
The risk factor profile for hemorrhagic stroke in the ACS setting was similar to the 
risk factor profile for ischemic stroke except for higher prevalence of valvular heart disease 
and left main stem disease, and greater use of thrombectomy in those with ischemic strokes, 
while patients with hemorrhagic strokes were more likely to have a diagnosis of 
hyperlipidemia and were more often treated with thrombolysis.  
Tables 2 & 3 show the significant independent predictors of ischemic stroke and 
hemorrhagic stroke outcomes stratified by the clinical setting of the PCI procedure. Only 
female sex and the requirement for glycoprotein IIb/IIIa inhibitors significantly predicted 
ischemic stroke post elective PCI. Older age, female sex, previous history of stroke and 
CABG, prior use of warfarin, presentation with STEMI, cardiogenic shock, the requirement 
of circulatory and ventilatory support, and thrombectomy were identified as significant 
predictors of ischemic stroke following PCI for ACS.   
Independent predictors of hemorrhagic stroke in elective PCI included female sex, 
history of previous stroke, previous PCI and glycoprotein IIb/IIIa inhibitor use, whilst older 
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age, previous PCI, STEMI, cardiogenic shock, requirement for circulatory and ventilator 
support, and thrombolysis were independent predictors of hemorrhagic stroke in the PCI for 
ACS setting.  
Table 4 & Supplementary Table 2 shows the association between the occurrence of 
a stroke complication and in-hospital MACE and 30-day mortality following multivariate 
analysis, both for the individual stroke subtypes and the combined stroke cohort. All analyses 
consistently show that having a stroke complication (either ischemic or hemorrhagic stroke) 
was significantly associated with poor outcomes assessed regardless of the clinical setting in 
which it occurred. Finally, ischemic stroke complications following PCI for ACS were 
associated with a significantly increased risk of in-hospital MACE but not 30-day mortality 
after controlling for various potential confounders compared to stroke complications after 
elective PCI.  
Supplementary Table 3 shows the results with logistic regression following 
propensity score matching.  This analysis suggests a significant increase in in-hospital MACE 
for total and ischemic stroke in both settings.  There were insufficient events to perform the 
propensity score matching analysis for hemorrhagic stroke.  After propensity score matching, 
there were significant increases in in-hospital MACE for ischemic and any stroke following 
both PCI procedures.  For 30-day mortality, similar significant increases were observed 
except for any stroke in elective patients. 
 
Discussion 
  
Our analysis of the UK national PCI database of over half a million patients 
undergoing PCI suggests that stroke is very uncommon after PCI. However, once stroke 
occurs as a complication of PCI, 30-day mortality and MACE are high, both in cerebral 
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infarcts and hemorrhages. Surprisingly the odds of both these complications are higher 
following an elective procedure than for ACS, as patients with ACS are likely to be sicker 
and have a worse risk profile compared to elective patients. Patients undergoing elective PCI 
were usually treated with clopidogrel at the time of the procedure, while the majority of 
patients undergoing emergency PCI were more likely to be on newer oral antiplatelet 
therapies such as ticagralor and prasugrel and also be treated with glycoprotein IIb/IIIa 
inhibitors that have more potent anti-platelet inhibition properties. This could potentially have 
had a protective effect in relation to ischemic stroke but also increase the risk of death after 
intracerebral hemorrhage in the ACS group.  
Our work provides insight to the outcomes associated with this rare but devastating 
complication of PCI to the stroke physician, who may not frequently encounter such patients 
frequently treated with potent anti-platelet and anti-coagulant therapies, which are 
necessitated during the PCI procedure. To our knowledge, this is the first paper to examine 
the determinants and outcomes of stroke following PCI by the indication as well as by 
specific stroke subtype. The key strength of our work is its large sample size and our ability 
to control for various potential confounders in an unselected cohort of patients undergoing 
PCI. 
 Our data builds on the report of Werner and colleagues who examined stroke risk 
stratified by the clinical setting of the PCI procedure [2], by additionally demonstrating that 
risk factors for ischemic and hemorrhagic stroke also vary by the clinical setting of the PCI 
procedure. Cardiovascular risk factors appear to be major determinants of risk of developing 
ischemic stroke in ACS setting, whilst the stroke risk for elective PCI is associated with 
glycoprotein IIb/IIIa usage. This observation may relate to the fact that glycoprotein IIb/IIIa 
is used in higher thrombotic risk patients in the elective setting (such as diabetics or those 
patients undergoing complex procedures) who are at higher risk of sustaining ischemic events 
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such as strokes [13,14]. It is possible that use of these agents is a marker for the various 
procedural complications or complexities that led an operator to use these agents. Supporting 
the findings from TOTAL [15], thrombectomy usage is also predictive of ischemic stroke 
after PCI for ACS. An important observation is the higher ischemic stroke risk observed for 
women for both indications for PCI (OR 2.62 and 1.78 respectively) compared to men.    
It is interesting that age appears to be predictive of stroke complications only in ACS 
setting but not in elective PCI setting once potential confounders were adjusted for. Similar 
results are observed for risk of hemorrhagic stroke. Thus, age per se is not a risk factor for a 
stroke complication sustained following elective PCI. Werner and colleagues reported overall 
in-hospital mortality of 19.2% for patients who developed stroke (elective PCI, 10.0%; PCI 
for ACS, 23.2%) compared with 1.3% for those without stroke (elective PCI, 0.2%; PCI for 
ACS, 2.3%). These results are similar to the 30-day mortality reported in the current study of 
18.9% (elective PCI, 6.7%; PCI for ACS, 21.2%) for those who developed stroke compared 
with 2.0% for those who did not (elective PCI, 0.3%; PCI for ACS, 3.2%).  
We found the risk of adverse outcome (in-hospital MACE or 30-day mortality) to be 
significantly higher in patients where PCI was complicated by a stroke regardless of stroke 
subtype or the clinical setting that it occurred in. Whilst this finding is not unexpected, we 
found that the greatest observed risk for adverse outcomes is associated with in-hospital 
strokes complicating elective PCI. This appears to be more pronounced in hemorrhagic stroke 
albeit with large estimates perhaps contributed by the relatively small sample size compared 
to ischemic stroke.  Finally, once stroke has occurred, the further risk of MACE and 30-day 
mortality is high, but not significantly different between the two settings. Considering that 
patients with PCI have significant cardiovascular morbidity in addition to the stroke, it is not 
surprising. 
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Our study has several strengths. The BCIS dataset includes >95% of all PCI 
procedures performed in the UK which therefore reflects a national, real-world experience 
that includes high-risk patients encountered in daily interventional practice who are often 
excluded from randomized controlled trials. Whilst stroke is a relatively rare complication of 
PCI, its impact on mortality and morbidity and residual long-term disability has profound 
consequences not only for patients and their carers but also purchasers and providers of 
healthcare. Our large sample size allows us to study risk factors for sustaining a stroke 
complication following two clinical settings in which PCI is performed, as well as enabling 
us to compare and contrast the risk of adverse outcomes by the clinical setting and also 
provide stroke subtype specific prognostic information in these settings. This will enable 
stroke physicians to better counsel patients and their families regarding outcomes. 
 There are also limitations in this study. Our dataset does not capture the timing and 
severity of stroke, stroke nature and ADL score. We are unable to ascertain the temporal 
relationship between the predictor and stroke event. For example, it is possible that patients 
who undergo ventilation are more likely to develop stroke but patients might also be 
ventilated as a consequence of developing stroke or patients who were admitted with a 
myocardial infarction may have sustained a stroke as a consequence of the coronary event 
rather than the procedure itself. However, the primary focus is to compare and contrast risk 
factors and outcomes of each stroke subtype for each type of PCI procedure. As highlighted 
in our previous work [4] the diagnosis of stroke is reported by individual operators with no 
external validation, or information how the diagnosis was reached or what imaging 
modalities were used to ascertain etiology hence there is the potential for under-reporting or 
misclassification of neurological events. In the UK however, it is standard practice that 
anyone who sustains a stroke is referred to a stroke team who would organize the relevant 
neuroimaging, confirm the diagnosis and offer guidance in management of the patient. 
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Furthermore, our reported incident stroke rates are similar in magnitude to those reported in 
the national NCDR [2] and the SCAAR [16] datasets derived from USA and Sweden 
respectively. Given the smaller proportion of hemorrhagic strokes within the total stroke 
population in this cohort, even with over half a million PCI procedures, we were not able to 
perform propensity score matched analyses. Finally, whilst the BCIS dataset captures PCI 
related complications, it does not capture information as to how these were managed or 
whether there were differences in the management of such complications between units. 
In summary, we found that stroke after both the elective and ACS setting is associated 
with adverse outcomes, irrespective of stroke subtype. Our study provides a better 
understanding of the risk factors as well as outcomes for stroke following PCI by procedure 
type as well as specific stroke subtype. This will inform both clinicians and patients on stroke 
risk associated in a specific PCI setting, but also provides important outcome information 
from a national perspective, to enable stroke physicians to counsel patients and their families 
around outcomes if such neurological complications occur, since stroke complications 
occurring in this setting will represent a small proportion of stroke physicians case mix.  
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Table 1: Sample characteristics between those who had stroke complication compared with those who did not by type of PCI procedure 
for ischemic and hemorrhagic stroke 
Variable  No stroke 
elective   
Ischemic 
stroke 
elective 
P No stroke 
non-elective 
Ischemic 
stroke  
non-
elective  
P No stroke 
elective   
Hemorrhag
ic stroke 
elective 
P Hemorrhag
ic stroke 
non-
elective 
P 
Age (years)  65.3±10.6 67.5±10.2 0.048 64.3±12.5 69.7±12.2 <0.001 65.3±10.6 67.8±9.9 0.19 69.3±10.9 <0.001 
Female 57,572 (25%) 42 (46%) <0.001 87,518 (27%) 201 (42%) <0.001 57,572 (25%) 10 (45%) 0.025 45 (39%) 0.003 
Diagnosis 
Stable angina 
 
NSTEMI 
STEMI 
 
218,300 
(100%) 
5 (0%) 
0 (0%) 
 
90 (100%) 
 
0 (0%) 
0 (0%) 
0.96  
834 (0.3%) 
 
205,740 (67%) 
102,189 (33%) 
 
0 (0%) 
 
181 (41%) 
256 (59%) 
<0.001  
218,300 
(100%) 
5 (0%) 
0 (0%) 
 
21 (100%) 
 
0 (0%) 
0 (0%) 
0.98 
 
 
 
 
0 (0%) 
 
41 (46%) 
48 (54%) 
<0.001 
Smoking status 
Never smoked 
Ex-smoker 
Current smoker 
 
78,871 (40%) 
93,682 (47%) 
25,491 (13%) 
 
44 (52%) 
33 (39%) 
7 (8%) 
0.055  
94,614 (33%) 
101,110 (35%) 
91,583 (32%) 
 
155 (38%) 
134 (33%) 
121 (30%) 
0.11  
79,871 (40%) 
93,682 (47%) 
25,491 (13%) 
 
9 (47%) 
10 (53%) 
0 (0%) 
0.24  
38 (37%) 
39 (38%) 
25 (25%) 
0.28 
Hypertension 129,431 
(58%) 
51 (59%) 0.91 155,469 (49%) 236 (50%) 0.44 129,431 (58%) 13 (57%) 0.92 60 (52%) 0.49 
Hypercholesterolemia 139,321 
(62%) 
58 (67%) 0.42 160,693 (50%) 228 (49%) 0.51 139,321 (62%) 15 (68%) 0.58 47 (41%) 0.038 
Diabetes 46,035 (21%) 21 (24%) 0.57 55,262 (18%) 83 (18%) 0.95 46,035 (21%) 3 (14%) 0.39 24 (21%) 0.31 
Previous myocardial 
infarction 
68,895 (34%) 29 (35%) 0.87 71,445 (24%) 108 (25%) 0.88 68,985 (34%) 4 (22%) 0.31 29 (26%) 0.66 
Previous stroke 7,610 (3%) 5 (6%) 0.23 12,811 (4%) 40 (9%) <0.001 7,610 (3%) 3 (14%) 0.008 9 (8%) 0.039 
Peripheral vascular 
disease 
10,834 (5%) 4 (5%) 0.91 14,571 (5%) 36 (8%) 0.001 10,834 (5%) 2 (9%) 0.36 10 (9%) 0.035 
Renal disease 5,106 (2%) 1 (1%) 0.49 8,921 (3%) 20 (4%) 0.043 5,106 (2%) 1 (5%) 0.46 8 (7%) 0.007 
Valvular heart 
disease 
3,221 (1%) 2 (2%) 0.50 3,192 (1%) 9 (2%) 0.045 3,221 (1%) 0 (0%) 0.57 0 (0%) 0.28 
Previous PCI 70,388 (32%) 32 (36%) 0.48 48,826 (16%) 69 (15%) 0.66 70,388 (32%) 9 (41%) 0.37 21 (18%) 0.35 
Previous CABG 92,982 (40%) 36 (40%) 0.91 121,073 (37%) 149 (31%) 0.012 92,982 (40%) 12 (55%) 0.17 31 (27%) 0.020 
Cardiogenic shock 0 (0%) 0 (0%) 0.76 10,755 (3%) 81 (17%) <0.001 0 (0%) 0 (0%) - 25 (22%) <0.001 
Receipt of ventilation 0 (0%) 0 (0%) 0.62 6,582 (2%) 50 (11%) <0.001 0 (0%) 0 (0%) - 13 (12%) <0.001 
Circulatory support 461 (0.2%) 0 (0%) 0.65 8,119 (3%) 79 (17%) <0.001 461 (0.2%) 2 (9%) <0.001 19 (17%) <0.001 
Antiplatelet therapy   0.55   0.13   0.89  0.18 
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Clopidogrel 
Prasugrel 
Ticagrelor 
168,845 
(98%) 
1,717 (1%) 
1,020 (0.6%) 
73 (100%) 
0 (0%) 
0 (0%) 
217,872 (89%) 
16,108 (7%) 
11,774 (5%) 
311 (86%) 
33 (9%) 
19 (5%) 
167,845 (98%) 
1,717 (1%) 
1,020 (0.6%) 
15 (100%) 
0 (0%) 
0 (0%) 
84 (94%) 
4 (4%) 
1 (1%) 
Warfarin use 2,822 (1%) 1 (1%) 0.92 2,405 (0.8%) 10 (2%) 0.001 2,822 (1%) 1 (5%) 0.14 3 (3%) 0.022 
Glycoprotein IIb/IIIa 
inhibitor use 
19,720 (9%) 30 (34%) <0.001 101,572 (33%) 232 (50%) <0.001 19,720 (9%) 8 (38%) <0.001 49 (42%) 0.038 
Thrombectomy use 0 (0%) 0 (0%) - 46,927 (15%) 129 (28%) <0.001 0 (0%) 0 (0%) - 20 (18%) 0.55 
Left main stem 
disease 
7,970 (4%) 5 (6%) 0.33 10,501 (3%) 29 (6%) <0.001 7,970 (4%) 3 (14%) 0.009 7 (6%) 0.10 
Thrombolysis 0 (0%) 0 (0%) - 22,100 (8%) 35 (8%) 0.84 0 (0%) 0 (0%) - 30 (27%) <0.001 
In-hospital MACE 2,303 (1%) 23 (25%) <0.001 9,363 (3%) 122 (26%) <0.001 2,303 (1%) 4 (18%) <0.001 43 (37%) <0.001 
Death at 30 days 757 (0.3%) 6 (7%) <0.001 10,350 (3%) 99 (21%) <0.001 757 (0.3%) 10 (45%) <0.001 57 (51%) <0.001 
PCI=percutaneous coronary intervention, CABG=coronary artery bypass graft, MACE=major adverse cardiovascular event 
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Table 2: Significant predictors of ischemic stroke outcome by type of PCI 
Variables Elective PCI P Non-elective PCI P 
Age 1.01 (0.99-1.04) 0.19 1.03 (1.02-1.04) <0.001 
Female 2.52 (1.65-3.86) <0.001 1.78 (1.47-2.16) <0.001 
Smoking status 
Non-smoker 
Ex-smoker 
Current smoker 
 
1.00 (ref) 
0.74 (0.46-1.17) 
0.60 (0.26-1.39) 
 
- 
0.20 
0.23 
 
1.00 (ref) 
0.95 (0.76-1.20) 
1.07 (0.83-1.39) 
 
- 
0.70 
0.61 
Hypertension 0.86 (0.55-1.37) 0.53 0.95 (0.76-1.20) 0.64 
Hypercholesterolemia 1.26 (0.78-2.03) 0.35 1.08 (0.88-1.32) 0.48 
Diabetes 1.07 (0.65-1.76) 0.80 0.95 (0.74-1.22) 0.68 
Previous myocardial 
infarction 
1.06 (0.66-1.72) 0.81 1.08 (0.82-1.41) 0.59 
Previous stroke 1.67 (0.66-4.18) 0.28 1.70 (1.21-2.38) 0.002 
Peripheral vascular disease 0.81 (0.29-2.27) 0.70 1.31 (0.92-1.88) 0.14 
Renal disease 0.50 (0.07-3.65) 0.50 1.25 (0.78-1.98) 0.35 
Previous PCI 1.29 (0.80-2.06) 0.29 1.11 (0.82-1.50) 0.49 
Previous CABG 0.99 (0.65-1.52) 0.97 0.81 (0.66-0.99) 0.038 
Cardiogenic shock - - 1.48 (1.03-2.12) 0.032 
Receipt of ventilation - - 2.35 (1.64-3.37) <0.001 
Circulatory support - - 2.83 (2.02-3.97) <0.001 
Antiplatelet therapy* 
Clopidogrel 
Prasugrel 
Ticagrelor 
 
- 
- 
- 
-  
1.00 (ref) 
1.05 (0.71-1.56) 
1.02 (0.62-1.69) 
 
- 
0.81 
0.93 
Warfarin use 0.91 (0.13-6.62) 0.93 2.22 (1.17-4.18) 0.014 
Glycoprotein IIb/IIIa 
inhibitor use 
5.39 (3.40-8.55) <0.001 1.66 (1.36-2.03) <0.001 
Left main stem disease 1.28 (0.52-3.19) 0.59 1.12 (0.75-1.67) 0.57 
Thrombectomy - - 1.40 (1.10-1.77) 0.006 
Recent thrombolysis - - 1.20 (0.84-1.72) 0.32 
STEMI - - 1.94 (1.55-2.43) <0.001 
Year 
2006  
2007 
2008 
2009 
2010 
2011 
2012 
2013 
 
1.00 (ref) 
0.91 (0.39-2.12) 
1.28 (0.59-2.79) 
1.10 (0.48-2.54) 
1.36 (0.60-3.08) 
1.77 (0.81-3.88) 
1.17 (0.49-2.77) 
0.86 (0.33-2.25) 
 
- 
0.83 
0.53 
0.82 
0.46 
0.15 
0.73 
0.76 
 
1.00 (ref) 
1.01 (0.63-1.63) 
1.19 (0.76-1.87) 
0.80 (0.50-1.27) 
1.23 (0.79-1.90) 
0.85 (0.54-1.35) 
0.94 (0.60-1.49) 
0.92 (0.57-1.47) 
 
- 
0.97 
0.45 
0.35 
0.36 
0.49 
0.80 
0.72 
*Antiplatelet therapy excluded from the analysis of elective cases because of colinearity. 
PCI=percutaneous coronary intervention, CABG=coronary artery bypass graft 
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Table 3: Significant predictors of hemorrhagic stroke outcome by type of PCI  
Variables Elective PCI P Non-elective PCI P 
Age 1.02 (0.98-1.06) 0.40 1.03 (1.01-1.04) 0.003 
Female 2.65 (1.13-6.24) 0.026 1.57 (1.06-2.31) 0.024 
Smoking status* 
Non-smoker 
Ex-smoker 
Current smoker 
 
- 
- 
- 
-  
1.00 (ref) 
1.07 (0.68-1.69) 
0.83 (0.48-1.41) 
 
- 
0.77 
0.48 
Hypertension 0.87 (0.34-2.21) 0.78 1.16 (0.77-1.75) 0.48 
Hypercholesterolemia 1.41 (0.54-3.72) 0.48 0.67 (0.45-1.02) 0.061 
Diabetes 0.50 (0.14-1.73) 0.28 1.21 (0.75-1.94) 0.44 
Previous myocardial 
infarction 
0.64 (0.22-1.91) 0.43 0.90 (0.54-1.50) 0.68 
Previous stroke 4.07 (1.13-14.62) 0.031 1.53 (0.76-3.10) 0.24 
Peripheral vascular disease 1.26 (0.27-5.82) 0.76 1.58 (0.79-3.15) 0.20 
Renal disease 2.21 (0.28-17.17) 0.45 1.88 (0.89-3.99) 0.10 
Previous PCI 2.06 (0.83-5.13) 0.12 1.88 (1.08-3.29) 0.027 
Previous CABG 1.64 (0.70-3.87) 0.25 0.61 (0.40-0.93) 0.020 
Cardiogenic shock - - 2.34 (1.20-4.54) 0.012 
Receipt of ventilation - - 1.97 (0.97-3.98) 0.059 
Circulatory support - - 2.17 (1.11-4.27) 0.024 
Antiplatelet therapy* 
Clopidogrel 
Prasugrel 
Ticagrelor 
 
- 
- 
- 
-  
1.00 (ref) 
0.63 (0.21-1.87) 
0.28 (0.03-2.23) 
 
- 
0.40 
0.23 
Warfarin use 3.15 (0.41-24.06) 0.27 2.46 (0.77-7.87) 0.13 
Glycoprotein IIb/IIIa 
inhibitor use 
4.83 (1.95-12.01) 0.001 0.96 (0.64-1.44) 0.86 
Left main stem disease 4.11 (1.21-13.97) 0.024 1.12 (0.50-2.49) 0.79 
Thrombectomy - - 0.97 (0.57-1.64) 0.90 
Recent thrombolysis - - 3.91 (2.49-6.15) <0.001 
STEMI - - 3.44 (2.24-5.28) <0.001 
Year 
2006  
2007 
2008 
2009 
2010 
2011 
2012 
2013 
 
1.00 (ref) 
0.66 (0.16-2.76) 
0.87 (0.23-3.31) 
0.67 (0.16-2.89) 
0.76 (0.17-3.32) 
0.53 (0.10-2.83) 
0.25 (0.03-2.24) 
0.25 (0.03-2.27) 
 
- 
0.56 
0.84 
0.59 
0.72 
0.45 
0.22 
0.22 
 
1.00 (ref) 
0.92 (0.42-2.00) 
1.00 (0.47-2.11) 
1.08 (0.51-2.25) 
0.81 (0.37-1.77) 
0.24 (0.09-0.68) 
0.49 (0.20-1.18) 
0.54 (0.22-1.32) 
 
- 
0.83 
0.99 
0.85 
0.60 
0.007 
0.11 
0.18 
Smoking status and antiplatelet was omitted from the elective analysis because it is a perfect 
predictor. 
PCI=percutaneous coronary intervention, CABG=coronary artery bypass graft 
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Table 4: Risk of adverse outcomes (MACE or 30-d mortality) among patients who had any stroke, ischemic stroke and hemorrhagic stroke by 
elective or non-elective procedures  
 Crude rate for elective 
with stroke vs no 
stroke 
OR Elective  
(ref-no stroke) 
P Crude rate for non-
elective with stroke vs 
no stroke 
OR non-elective  
(ref. no stroke) 
p OR  Non-
elective  
Cf. elective 
among those 
who developed 
stroke post 
PCI 
(ref. elective) 
P 
Both type  
-MACE 
 
-30-d 
mortality 
 
27/113 (24%) vs 
2303/231664 (1%) 
16/122 (13%) vs 
757/227147 (0.3%) 
 
21.05 (13.25-33.44) 
 
37.90 (21.43-67.05) 
 
<0.001 
 
<0.001 
 
165/592 (28%) vs 
9363/328070 (3%) 
156/577 (27%) vs 
10350/320878 (3%) 
 
6.25 (5.03-7.77) 
 
5.00 (3.96-6.31) 
 
<0.001 
 
<0.001 
 
0.63  
(0.35-1.15) 
1.24  
(0.64-2.43) 
 
0.13 
 
0.52 
Ischemic 
-MACE 
 
-30-d 
mortality 
 
23/91 (25%) vs 
2303/231664 (1%) 
6/90 (6.7%) vs 
757/227147 (0.3%) 
 
25.13 (15.29-41.31) 
 
17.61 (7.51-41.33) 
 
<0.001 
 
<0.001 
 
122/475 (26%) vs 
9363/328070 (3%) 
99/466 (21%) vs 
10350/320878 (3%) 
 
5.48 (4.27-7.04) 
 
3.11 (2.34-4.13) 
 
<0.001 
 
<0.001 
 
0.44  
(0.22-0.86) 
1.70  
(0.64-4.53) 
 
0.016 
 
0.29 
Hemorrhagic  
-MACE 
 
-30-d 
mortality 
 
4/22 (18%) vs 
2303/231664 (1%) 
10/22 (45%) vs 
757/227147 (0.3%) 
 
8.67 
(2.48-30.27) 
175.24  
(67.69-453.66) 
 
0.001 
 
<0.001 
 
43/117 (37%) vs 
9363/328070 (3%) 
57/111 (51%) vs 
10350/320878 (3%) 
 
10.00  
(6.39-15.66) 
21.50  
(13.81-33.46) 
 
<0.001 
 
<0.001 
 
3.89  
(0.65-23.19) 
1.30  
(0.35-4.87) 
 
0.14 
 
0.70 
Adjusted for age, female gender, smoking status, hypertension, hypercholesterolemia, diabetes, previous myocardial infarction, previous stroke, 
peripheral vascular disease, renal disease, valvular heart disease, previous percutaneous coronary intervention and previous coronary artery 
bypass graft, cardiogenic shock, receipt of ventilation and circulatory support, antiplatelet use, warfarin use, glycoprotein IIb/IIIa inhibitor use, 
thrombectomy use, left main stem disease, thrombolysis use, STEMI diagnosis and year of PCI adjusted.  
MACE=major adverse cardiovascular event 
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SUPPLEMENTAL MATERIAL  
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Supplemental Methods 
The variables included as potential confounders in multiple logistic regression models 
were age, sex, smoking status (never smoked, ex-smoker, current smoker), presence of 
diabetes, hypertension, hyperlipidemia, previous myocardial infarction (MI), previous stroke, 
peripheral vascular disease, renal disease, valvular heart disease, previous PCI, previous 
coronary artery bypass graft, cardiogenic shock, use of circulatory support, use of 
thrombectomy, left main stem PCI, use of glycoprotein IIb/IIIa inhibitor, oral antiplatelets 
(clopidogrel, prasugrel, ticagrelor), warfarin, use of thrombolytic agents, and year of 
procedure. 
We used a step-wise modeling approach to better understand the associations and the 
following models were constructed; Model 1: unadjusted; Model 2: age, sex and smoking 
status adjusted; Model 3: as in model 2 and additional adjustment for hypertension, 
hypercholesterolemia, diabetes, previous myocardial infarction, previous stroke, peripheral 
vascular disease, renal disease, valvular heart disease, previous percutaneous coronary 
intervention and previous coronary artery bypass graft; Model 4: as in Model 3 with 
additional adjustment for cardiogenic shock, receipt of ventilation and circulatory support; 
Model 5: as in Model 4 plus adjustment for antiplatelet use, warfarin use, glycoprotein 
IIb/IIIa inhibitor use, thrombectomy use, left main stem disease, thrombolysis use, STEMI 
diagnosis and year of PCI.  These results are presented in Supplementary Table 2 and Model 
5 is presented in Table 4.    
To account for baseline differences across stroke groups, multiple imputations with 
propensity score matching (mi estimate: teffects psmatch on Stata) was used to estimate the 
average treatment effect (ATE).  The method was used to analyze two separate logistic 
treatment models (ischemic stroke vs. no stroke and any stroke vs. no stroke), calculating 
propensity scores for group membership.  Analysis for hemorrhagic stroke vs. no stroke was 
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not possible because of too low propensity scores for many cases.  Standard settings for the 
matching algorithm were used with a minimum of one neighbor requested for all 
observations and potential matches considered regardless of how dissimilar their propensity 
score.  Tolerance for the overlap assumption was set to 10-5.  We excluded variables which 
were perfect predictors from the propensity matching analysis. 
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Supplementary Table I: Missing data table 
Variable Data available Missing data % 
missing 
Age 560,439 0 0 
Female 560,439 0 0 
Smoking status 485,966 74,473 13 
Hypertension 544,210 16,229 3 
Hypercholesterolemia 544,210 16,229 3 
Diabetes 529,247 31,192 6 
Previous myocardial infarction 498,798 61,641 11 
Previous stroke 544,210 16,229 3 
Peripheral vascular disease 544,210 16,229 3 
Renal disease 556,005 4,434 0.8 
Valvular heart disease 544,210 16,229 3 
Previous PCI 534,219 26,220 5 
Previous CABG 560,439 0 0 
Cardiogenic shock 517,569 42,870 8 
Ventilated 462,794 97,645 17 
Circulatory support 515,176 45,263 8 
Antiplatelet therapy 417,266 143,173 26 
Warfarin 516,457 43,982 8 
Glycoprotein IIb/IIIa inhibitor 516,790 43,649 8 
Thrombectomy 537,922 22,517 4 
Left main stem disease 539,136 21,303 4 
Recent thrombolysis 509,443 50,996 9 
STEMI 560,439 0 0 
MACE 560,439 0 0 
Mortality at 30 days 548,714 11,725 2 
PCI=percutaneous coronary intervention, CABG=coronary artery bypass graft, 
MACE=major adverse cardiovascular event 
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Supplementary Table II: Risk of adverse outcomes (MACE or 30-d mortality) among patients who had any stroke, ischemic stroke and 
hemorrhagic stroke by elective or non-elective procedures  
 OR Elective  
(ref-no stroke) 
P OR non-elective  
(ref. no stroke) 
p OR  Non-elective  
Cf. elective among 
those who developed 
stroke post PCI 
(ref. elective) 
p 
Both type  
-MACE 
    Model 1 
    Model 2 
    Model 3 
    Model 4 
    Model 5 
-30-d mortality* 
    Model 1 
    Model 2 
    Model 3 
    Model 4 
    Model 5 
 
 
31.27 (20.25-48.27) 
29.35 (18.97-45.42) 
29.58 (19.07-45.90) 
29.17 (18.64-45.66) 
21.05 (13.25-33.44) 
 
49.84 (29.22-85.02) 
45.97 (26.58-79.50) 
46.97 (26.91-81.99) 
46.21 (26.33-81.09) 
37.90 (21.43-67.05) 
 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
 
 
13.15 (10.98-15.76) 
11.23 (9.34-13.51) 
10.87 (9.02-13.10) 
7.47 (6.00-9.29) 
6.25 (5.03-7.77) 
 
11.12 (9.24-13.37) 
9.26 (7.64-11.21) 
9.12 (7.51-11.07) 
6.05 (4.79-7.64) 
5.00 (3.96-6.31) 
 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
 
 
1.23 (0.77-1.97) 
1.20 (0.74-1.95) 
1.14 (0.69-1.89) 
0.84 (0.49-1.42) 
0.63 (0.35-1.15) 
 
2.22 (1.27-3.89) 
2.06 (1.16-3.67) 
1.98 (1.09-3.58) 
1.54 (0.84-2.83) 
1.24 (0.64-2.43) 
 
 
0.39 
0.46 
0.61 
0.51 
0.13 
 
0.005 
0.014 
0.024 
0.16 
0.52 
Ischemic 
-MACE 
    Model 1 
    Model 2 
    Model 3 
    Model 4 
    Model 5 
-30-d mortality 
    Model 1 
    Model 2 
    Model 3 
 
 
33.69 (20.96-51.14) 
31.70 (19.68-51.09) 
32.18 (19.93-51.96) 
33.94 (21.03-54.78) 
25.13 (15.29-41.31) 
 
21.36 (9.30-49.05) 
19.21 (8.27-44.63) 
19.73 (8.45-46.05) 
 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
 
<0.001 
<0.001 
<0.001 
 
 
11.76 (9.57-14.47) 
9.94 (8.05-12.27) 
9.72 (7.85-12.02) 
6.57 (5.11-8.43) 
5.48 (4.27-7.04) 
 
8.09 (6.48-10.11) 
6.53 (5.19-8.22) 
6.46 (5.12-8.16) 
 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
 
<0.001 
<0.001 
<0.001 
 
 
1.02 (0.61-1.71) 
1.00 (0.58-1.71) 
0.88 (0.50-1.54) 
0.61 (0.34-1.09) 
0.44 (0.22-0.86) 
 
3.78 (1.60-8.90) 
3.25 (1.36-7.78) 
2.82 (1.16-6.84) 
 
 
0.94 
1.00 
0.66 
0.094 
0.016 
 
0.002 
0.008 
0.022 
24 
 
    Model 4 
    Model 5 
21.18 (9.08-49.38) 
17.61 (7.51-41.33) 
<0.001 
<0.001 
3.76 (2.82-5.00) 
3.11 (2.34-4.13) 
<0.001 
<0.001 
2.04 (0.83-5.05) 
1.70 (0.64-4.53) 
0.12 
0.29 
Hemorrhagic  
-MACE 
    Model 1 
    Model 2 
    Model 3 
    Model 4 
    Model 5 
-30-d mortality 
    Model 1 
    Model 2 
    Model 3 
    Model 4 
    Model 5 
 
 
22.13 (7.48-65.44) 
20.59 (6.94-61.11) 
20.04 (6.67-60.23) 
12.97 (3.69-45.57) 
8.67 (2.48-30.27) 
 
249.22 (107.35-578.57) 
255.77 (105.52-619.98) 
278.98 (113.23-687.36) 
221.14 (87.67-557.80) 
175.24 (67.69-453.66) 
 
 
<0.001 
<0.001 
<0.001 
<0.001 
0.001 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
 
 
19.78 (13.58-28.82) 
17.60 (11.99-25.83) 
16.36 (11.11-24.10) 
11.93 (7.60-18.74) 
10.00 (6.39-15.66) 
 
31.67 (21.82-45.97) 
29.69 (20.13-43.81) 
28.48 (19.23-42.18) 
26.24 (16.90-40.74) 
21.50 (13.81-33.46) 
 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
 
 
2.61 (0.83-8.23) 
2.81 (0.81-8.75) 
3.63 (0.92-14.34) 
3.99 (0.89-17.88) 
3.89 (0.65-23.19) 
 
1.27 (0.51-3.17) 
1.37 (0.51-3.66) 
1.73 (0.60-5.04) 
1.49 (0.49-4.59) 
1.30 (0.35-4.87) 
 
 
0.10 
0.10 
0.066 
0.070 
0.14 
 
0.61 
0.53 
0.31 
0.49 
0.70 
Model 1: unadjusted. 
Model 2: age, female gender and smoking status adjusted. 
Model 3: Model 2 + hypertension, hypercholesterolemia, diabetes, previous myocardial infarction, previous stroke, peripheral vascular disease, 
renal disease, valvular heart disease, previous percutaneous coronary intervention and previous coronary artery bypass graft adjusted. 
Model 4: Model 3 + cardiogenic shock, receipt of ventilation and circulatory support adjusted. 
Model 5: Model 4 + antiplatelet use, warfarin use, glycoprotein IIb/IIIa inhibitor use, thrombectomy use, left main stem disease, thrombolysis 
use, STEMI diagnosis and year of PCI adjusted.  
MACE=major adverse cardiovascular event 
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Supplementary Table III: Propensity score matched results for risk of in-hospital MACE and 30-day mortality for ischemic stroke and any 
stroke  
 
Analysis Method Group Coefficient 95% CI p-value 
In-hospital 
MACE 
Propensity score 
matching, ATE 
No stroke in elective patient Reference    
Ischemic stroke in elective patient 0.1648 0.0632 0.2664 0.002 
Propensity score 
matching, ATE 
No stroke in non-elective patient Reference    
Ischemic stroke in non-elective 
patient 
0.1063 0.0603 0.1523 <0.001 
Propensity score 
matching, ATE 
No stroke in elective patient Reference    
Any stroke in elective patient 0.1346 0.0663 0.2028 <0.001 
Propensity score 
matching, ATE 
No stroke in non-elective patient Reference    
Any stroke in non-elective patient 0.1216 0.0809 0.1623 <0.001 
30-day 
mortality 
Propensity score 
matching, ATE 
No stroke in elective patient Reference    
Ischemic stroke in elective patient 0.0321 0.0001 0.0640 0.049 
Propensity score 
matching, ATE 
No stroke in non-elective patient Reference    
Ischemic stroke in non-elective 
patient 
0.0703 0.0331 0.1076 <0.001 
Propensity score 
matching, ATE 
No stroke in elective patient Reference    
Any stroke in elective patient 0.0770  -0.0066 0.1606 0.069 
Propensity score 
matching, ATE 
No stroke in non-elective patient Reference    
Any stroke in non-elective patient 0.1141 0.0732 0.1549 <0.001 
MACE=major adverse cardiovascular event, ATE=average treatment effect 
 
26 
 
